Loading...
•
Sep 30, 2023
Edgewise Therapeutics Q3 2023 Earnings Report
Edgewise Therapeutics reported financial results for the third quarter of 2023 and recent business highlights.
Key Takeaways
Edgewise Therapeutics reported a net loss of $25.7 million for the third quarter of 2023. The company is advancing clinical trials for EDG-5506 and EDG-7500, including the initiation of the GRAND CANYON pivotal study in Becker muscular dystrophy and the FOX Phase 2 trial in Duchenne muscular dystrophy.
Initiated GRAND CANYON, a global pivotal study of EDG-5506 in Becker muscular dystrophy.
Expanded Phase 2 LYNX trial of EDG-5506 including a new cohort for boys with Duchenne not currently treated with corticosteroids.
Initiated new Phase 2 FOX trial in boys with Duchenne muscular dystrophy who have been previously treated with gene therapy.
Advancing Phase 1 trial of EDG-7500, a novel sarcomere modulator for hypertrophic cardiomyopathy.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...